Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer - ScienceDirect
Cancers | Free Full-Text | Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 ...
CONSORT diagram. Disposition of patients in the ADAPT (Adjuvant Dynamic... | Download Scientific Diagram
Anti-HER2 Therapies in Breast Cancer
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic | npj Breast Cancer
ADAPT Umbrella trial design. Patients are included in the trial based... | Download Scientific Diagram
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer in: Journal of the National Comprehensive Cancer Network Volume 20 Issue 6 (2022)
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study - The Lancet Diabetes & Endocrinology
ADAPT HER2+/HR- trial design. HER2+/HR- patients receive either dual... | Download Scientific Diagram
CCO Independent Conference Coverage - ppt download
PDF) WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: Study protocol for a prospective, multi-center, controlled, non-blinded, randomized ...
Case 3: POETIC and ADAPT Trials in HR+ High-Risk Breast Cancer
Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status? - Nadia Harbeck, 2018
Dr. Harbeck on Key Results From the WSG ADAPT-TP Trial in HER2+, HR+ Breast Cancer
Susan G. Komen on X: "WSG ADAPT HR-/HER2+ phase II trial showed improved pathological complete response (pCR) and survival in patients treated by #de-escalated chemotherapy, pertuzumab, and trastuzumab. Early pCR strongly associated
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial - The Lancet Oncology
OncoAlert on X: "The #OncoAlertTopTweet 🚨Day5⃣of #ESMO21 Tweet @Dr_Ivanoncologo Dr. Harbeck: Predictive impact of biomarkers🎯on pCR and survival after de-escalated neoadjuvant T-DM1 w/ or w/o endocrine therapy (ET) vs Trastuzumab🧪+ ET in
ADAPT Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer - The ASCO Post
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator ...
Adaptive design (medicine) - Wikipedia
Novel Adapted-Response Clinical Trial Identifies Patients With Early Breast Cancer Who May Benefit From Dual HER2 Blockade Alone Without Chemotherapy
ADAPT Triple Negative trial design. Triple negative (HER2-/HR-)... | Download Scientific Diagram
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer - ScienceDirect
WSG-ADAPT HR+/HER2− trial design. Reprinted from Hofmann et al. 14 HR,... | Download Scientific Diagram
